Table 8 Opinion of the scientific steering committee – addictive comorbidity

• In general, aripiprazole is a relevant choice for the treatment of patients with schizophrenia and an addictive comorbidity

• Aripiprazole should be considered as an appropriate choice for patients requiring a first-line antipsychotic treatment for a first psychotic episode who have a cannabis use disorder

• Aripiprazole should be considered as an appropriate therapeutic alternative for patients with an addictive comorbidity who are poorly controlled on their current antipsychotic

• In contrast, the presence of an addictive comorbidity is not a sufficient reason to switch a patient who is well-controlled on current medication to aripiprazole

• Management of patients with schizophrenia and an addictive comorbidity should involve both antipsychotic treatment, with for example aripiprazole, and therapies targeted specifically at reducing substance misuse